Treatment of hepatitis C in patients with HIV

The Lancet HIV

Volumn 2, Issue 8, 2015, Pages e308-e309

  Tang, Lydia ^a   Kottilil, Shyam ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG EFFICACY; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS LOAD; COMPLICATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; MALE;

ANTIVIRAL AGENTS; BENZOFURANS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; MALE; QUINOXALINES;

EID: 84947028968     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00128-9     Document Type: Note

References (15)

1. Mohd Hanafi ah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specifi c antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
3. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
4. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
5. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
6. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181: 844-51.
7. Graham CS, Baden LR, Yu E, et al. Infl uence of human immunodefi ciency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-69.
8. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313: 1232-39.
9. Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. Annual Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26,
10. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-31.
11. Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study. Annual Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26, 2015, Abstract 151LB.
12. Rockstroh JK, Nelson M, Katlama C, et al. Effi cacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised open-label trial. Lancet HIV; published online July 10. http://dx.doi.org/10.1016/S2352-3018(15)00114-9.
13. Roth D, Nelson D, Bruchfeld A, et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. 50th Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria; April 22-26, 2015. Abstract LP02.
14. Poordad F, Lawitz E, Gutierrez J, A, et al. C-SWIFT: Grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6, or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. 50th Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria; April 22-26, 2015. Abstract O-006.
15. Centers for Disease Control and Prevention. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV-United States, 2011. MMWR Morb Mortal Wkly Rep 2014; 63: 1113-17.